Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Reaction Biology launches ion channel division

Reaction Biology Corporation, a leading contract research organization providing early-stage drug discovery services, announced that it has launched a new division to provide ion-channel discovery services.

Read More »

Vertex picks CF triple combos for Phase III trials

Vertex Pharmaceuticals selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients.

Read More »

Ferring’s Zomacton Receives FDA Approval to Treat Growth Hormone Deficiency in Adults

Ferring Pharmaceuticals Inc. announced that the U.S. FDA approved Zomacton (somatropin) for Injection 5 mg and 10 mg recombinant human growth hormone (GH) indicated for replacement of GH in adults with GH deficiency.

Read More »

North Korea threats spur U.S. search for new radiation therapies

The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome.

Read More »

Vical Terminates 54 Percent of Workforce to Focus Resources on Two Clinical Programs

Following a failed Phase III vaccine for stem cell transplant recipients, San Diego-based Vical Incorporated is slashing 54 percent of its employees and focusing the company’s remaining resources on two mid-stage candidates.

Read More »

Director of CDC resigns over financial conflicts: officials

Dr. Brenda Fitzgerald resigned her post as director of the U.S. Centers for Disease Control and Prevention over financial conflicts of interest, the U.S. Department of Health and Human Services (HHS) said.

Read More »

Seattle Genetics Snaps Up Cascadian in $614 Million Buyout Deal

Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.

Read More »

Agency Exec Shaun Urban Joins Inception Companies

The Inception Companies announce that Shaun Urban, former Managing Partner of Ogilvy CommonHealth, joined the organization as President.

Read More »

Bellicum’s cancer drug trials on clinical hold

Bellicum Pharmaceuticals Inc. said the FDA placed a clinical hold on U.S. trials of the company’s experimental cancer drug after three cases of brain disease linked to head trauma.

Read More »

U.S. judge sentences Novelion’s Aegerion

A federal judge sentenced Aegerion for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the victims.

Read More »

Global cancer survival rates improve, but wide gaps remain

Cancer patients’ survival prospects are improving – even for some of the deadliest types such as lung cancer – but there are huge disparities between countries, particularly for children, according to a published study.

Read More »

Health investors roll out unwelcome mat for Amazon’s arrival

Investors for months have fretted over a potential Amazon entry into healthcare delivery, particularly selling prescription drugs.

Read More »

Shire Snaps Up Rights to Preclinical Autoimmune Candidate for Undisclosed Sum

Rare disease giant Shire plc purchased a preclinical autoimmune drug candidate being developed by AB Biosciences.

Read More »

BridgeBio Launches QED Therapeutics With $65 Million, Abandoned Novartis Cancer Program

Palo Alto, Calif.-based BridgeBio Pharma is launching a new spinout to develop a recently abandoned Novartis cancer treatment now in its possession.

Read More »

FDA asks drugmakers to limit amount of opioid drug in packaging

The U.S. Food and Drug Administration is asking manufacturers of a common opioid medicine to change the way the drug is packaged, as part of efforts to deter its abuse amid an opioid epidemic in the United States.

Read More »

Pfizer Confirms Neuroscience Cuts, Shelves Another Four Early-Stage Projects

Pfizer released an update of the company’s pipeline, including eight different discontinued projects in the field of neuroscience.

Read More »

Eisai and Boston University School of Medicine Announce Research Collaboration to Study the Effects of Alzheimer’s Disease-associated Genetic Variants on Brain

Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer’s disease-associated genetic variants on the behavior of brain cells, called microglia.

Read More »

Amazon, Berkshire, JPMorgan create healthcare company to cut costs Inc., Berkshire Hathaway and JPMorgan Chase & Co. will form a healthcare company aimed at cutting costs for their U.S. employees, they said on Tuesday, sending shares in the broad healthcare sector sharply lower.

Read More »

Corbus CF drug to get FDA review on flare-up data

Corbus Pharmaceuticals Holdings Inc said the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function.

Read More »

FDA Grants Breakthrough Therapy Designation To Roche’s Autism Drug

An experimental Roche drug designed to improve social interaction in people with autism scored the U.S. Food and Drug Administration’s Breakthrough Therapy Designation.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom